262P Breast cancer recurrence: Prognostic factors and the relation with adherence to medical standards

Abstract

and correlation models determined associations between OHAs and survivals.Results: 108 patients (52%) were diabetic. Of these, 69 received metformin, 43 sulfonylureas, 7 thiazolideniodiones, 21 DPP inhibitors, and 32 insulin. Age of diabetics were 58.6 yr v 53.2 yr,p¼0.0018. Metformin prescribed more to luminal patients v non-luminal (57 v 26%, p¼0.002); luminal diabetics on metformin were 71% v 55 % non-luminal,p¼ 0.18 After a median follow-up of 10 years, the full diabetic cohort had a non-significant trend to shorter median overall survival (OS) relative to nondiabetics (91.5 v 99.8 months, p¼0.13). The median OS of all patients taking OHAs was similar to those not (95 v 96 months, p¼0.7). Those on metformin had a numerically longer median OS (95 v 88 months, p¼0.20) whereas those on sulfonylureas and those on insulin had numerically shorter median OS (92 v 97 months, p¼0.2 and 92 v 97 months, p¼0.3 respectively). BrCa specific median survival was 36 v 47 months for non-cancer related deaths, p ¼0.3. No impact of OHAs was noted when examining different sub-types. Regression analysis revealed no significant association of metformin (p¼0.50), T2DM with metformin (p¼0.14), cause of mortality (0.22) with survival time and mortality. Further, correlation analysis suggest strong negative correlation was observed among them (r ¼ -0.84, p<0.0001).Conclusions: Metformin had no significant impact on survival outcomes in diabetic Indigenous patients with BrCa. Analysis of metabolic syndrome and diabetes in the context of a larger cohort is needed to exclude impact of anti-diabetic pharmacotherapy on prognosis.